Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

del(9)(q34q34)|t(9;9)(q34;q34) SET/NUP214

Written2018-01Jean-Loup Huret, Philippe Dessen

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
Atlas_Id 3446
Note Non-annotated chromosomal abnormality. Preliminary data :
if you are an author who wish to write a full paper/card on this translocation, go to  How to contribute

Clinics and Pathology

Disease Acute lymphoblastic leukemia/lymphoblastic lymphoma|Acute myeloid leukemia, NOS|Acute myelomonocytic leukemia (FAB type M4)|Acute undifferentiated leukemia|Bilineage or biphenotypic leukemia

Genes involved and Proteins

Gene NameSET
Location 9q34.11
Gene NameNUP214
Location 9q34.13

Bibliography

Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia
von Lindern M, Breems D, van Baal S, Adriaansen H, Grosveld G
Genes Chromosomes Cancer 1992 Oct;5(3):227-34
PMID 1384675
 
Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia
Kim J, Lee SG, Song J, Kim SJ, Rha SY, Lee KA, Park TS, Choi JR
Cancer Genet Cytogenet 2010 Sep;201(2):73-80
PMID 20682390
 
Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia
Rosati R, La Starza R, Barba G, Gorello P, Pierini V, Matteucci C, Roti G, Crescenzi B, Aloisi T, Aversa F, Martelli MF, Mecucci C
Haematologica 2007 Feb;92(2):232-5
PMID 17296573
 
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia
Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, Buijs-Gladdines J, Horstmann M, van Wering ER, Soulier J, Pieters R, Meijerink JP
Blood 2008 May 1;111(9):4668-80
PMID 18299449
 
SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines
Quentmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, Macleod RA, Drexler HG
J Hematol Oncol 2009 Jan 23;2:3
PMID 19166587
 
SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL
Ben Abdelali R, Roggy A, Leguay T, Cieslak A, Renneville A, Touzart A, Banos A, Randriamalala E, Caillot D, Lioure B, Devidas A, Mossafa H, Preudhomme C, Ifrah N, Dombret H, Macintyre E, Asnafi V
Blood 2014 Mar 20;123(12):1860-3
PMID 24449214
 
SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines
Quentmeier H, Schneider B, Röhrs S, Romani J, Zaborski M, Macleod RA, Drexler HG
J Hematol Oncol 2009 Jan 23;2:3
PMID 19166587
 
MRD analysis and treatment outcome in three children with SET-NUP214-positive hematological malignancies
Li WJ, Cui L, Gao C, Zhao XX, Liu SG, Xing YP, Zhang RD, Zhang DW, Wang B, Li ZG, Wu MY
Int J Lab Hematol 2011 Dec;33(6):e25-7
PMID 21679311
 


Translocations implicated (Data extracted from papers in the Atlas)

 del(9)(q34q34)|t(9;9)(q34;q34) SET/NUP214

External links

SET (9q34.11) NUP214 (9q34.13)

Mitelman databasedel(9)(q34q34)|t(9;9)(q34;q34) [Case List]    del(9)(q34q34)|t(9;9)(q34;q34) [Transloc-MCList] SET/NUP214 [Fusion-MCList]
COSMICHisto = - Site = haematopoietic_and_lymphoid_tissue (COSMIC)
arrayMap (UZH-SIB Zurich)[select an item]
 
 
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Nov 6 14:07:12 CET 2018


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.